Status: Not yet recruiting
A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer
This study constitutes an open-label, multi-cohort, multi-center Phase Ib/II clinical study, developed to assess the safety, tolerability, and therapeutic efficacy of SYS6090 injection when administered in combination with bevacizumab, or in triple combination with bevacizumab and chemotherapy, among patients diagnosed with advanced colorectal cancer.
Participants needed: 260
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.Updated: Aug 6, 2026Locations: 1
Eligibility criteria
Subjects must be ≥18 years of age. [+4]
Subjects with clinically active central nervous system metastases; [+6]